Semaglutide and cardiovascular outcomes
Research on semaglutide and major cardiovascular events.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 16, 18, 18, 47, 53.
New guidelines and consensus this year
- Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause SocietyMaturitas2026 Oct
- Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)Ann Intern Med2026 Aug
- Swiss obesity clinical practice guidanceSwiss Med Wkly2026 May 19
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE ApproachObesity (Silver Spring)2026 Apr
- [SEMERGEN position paper on chronic kidney disease]Semergen2026 Apr
All papers from the last 12 months
566 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetesJ Diabetes Metab Disord2026 DecPMID 42840232
- Incretin therapy prescription in a high cardiovascular risk population: Insights from a cardiology-based cardiometabolic programAm J Prev Cardiol2026 DecPMID 42828252
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trialJ Med Econ2026 DecPMID 42012820
- GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiersAnn Med2026 DecPMID 41999297Review
- Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysisRen Fail2026 DecPMID 41644273Meta-analysisSystematic review
- Calculating cost per event avoided using a composite number needed to treatJ Med Econ2026 DecPMID 41562647
- Weight gain, adipose tissue remodeling and cardiometabolic disease in people with HIVCurr Opin HIV AIDS2026 Nov 1PMID 42817202Review
- Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implicationsCurr Opin Nephrol Hypertens2026 Nov 1PMID 42683763Review
- From adiposity to multisystem morbidity: the case for weight loss as disease modificationLancet Diabetes Endocrinol2026 NovPMID 42660161Review
- Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial EmulationDiabetes Obes Metab2026 NovPMID 42642357
More cardiology trends
All specialties →Tirzepatide in cardiovascular disease
Research on tirzepatide, a dual GIP/GLP-1 receptor agonist, and heart and vascular outcomes.
Pulsed field ablation
An ablation energy for atrial fibrillation that uses electric fields instead of heat or cold.
Finerenone
A non-steroidal mineralocorticoid receptor antagonist studied in kidney disease and heart failure.
Left atrial appendage occlusion
Closing the left atrial appendage with a device to reduce stroke risk in atrial fibrillation.
Coronary drug-coated balloons
Balloons coated with an antiproliferative drug, used in coronary arteries.
Photon-counting CT
A newer CT detector technology, studied for cardiac and coronary imaging.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
semaglutide[tiab] AND (cardiovascular[tiab] OR "heart failure"[tiab] OR MACE[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.